



Arnoud J Templeton

Contact

Arnoud J Templeton

Publications (15)

Fischer S, Gillessen S, Stalder O, Terbuch A, Cathomas R, Schmid F, Zihler D, Müller-Stich B, Fankhauser C, Hirschi-Blickenstorfer A, Alex Kluth L, Seifert B, Templeton A, Mingrone W, Ufe M, Fischer N, Beyer J, Woelky R, Omlin A, Vogl U, Hoppe K, Kamradt J, Rothschild S, Rothermundt C. First Indicator of Relapse in Testicular Cancer and Implications for Follow-up: Analysis of the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS). *Eur Urol Open Sci* 2024; 68:68–74.

Neubauer M, Nicolas G, Bauman A, Fani M, Nitzsche E, Afshar-Oromieh A, Forrer F, Rentsch C, Stenner-Liewen F, Templeton A, Schäfer N, Wild D, Chirindel A, all investigators on behalf of the SSNM Therapy Working Group. Early response monitoring during [Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study. *Eur J Nucl Med Mol Imaging* 2023

Templeton A, Omlin A, Berthold D, Beyer J, Burger I, Eberli D, Engeler D, Fankhauser C, Fischer S, Gillessen S, Nicolas G, Kroeze S, Lorch A, Müntener M, Papachristofilou A, Schäfer N, Seiler D, Stenner-Liewen F, Tsantoulis P, Vlajnic T, Zilli T, Zwahlen D, Cathomas R. Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer. *Swiss Med Wkly* 2023; 153:40108.

Schlegel T, Hägele-Link S, Bertotto C, Rieger U, Wittchow S, Schlaeppi M, Templeton A. Diagnosis and Treatment of Patients Utilizing Complementary Medicine at a Tertiary Referral Hospital in Eastern Switzerland. *Complement Med Res* 2023

Fischer S, Rothermundt C, Stalder O, Terbuch A, Hermanns T, Zihler D, Müller-Stich B, Fankhauser C, Hirschi-Blickenstorfer A, Seifert B, Alex Kluth L, Ufe M, Mingrone W, Templeton A, Fischer N, Rothschild S, Woelky R, Gillessen S, Cathomas R. The Value of Tumour Markers in the Detection of Relapse—Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study. *Eur Urol Open Sci* 2023; 50:57–60.

Christiansen A, Lobo J, Fankhauser C, Rothermundt C, Cathomas R, Batavia A, Grogg J, Templeton A, Hirschi-Blickenstorfer A, Lorch A, Gillessen S, Moch H, Beyer J, Hermanns T. Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence. *Front Oncol* 2022; 12:1056823.

Neuenschwander A, Lonati C, Antonelli L, Papachristofilou A, Cathomas R, Rothermundt C, Templeton A, Gulamhusein A, Fischer S, Gillessen S, Hermanns T, Lorch A, Mattei A, Fankhauser C. Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review. *Eur Urol Focus* 2022

Adam R, Tibau A, Molto Valiente C, Seruga B, Ocana A, Amir E, Templeton A. Clinical benefit of cancer drugs approved in Switzerland 2010–2019. *PloS one* 2022; 17:e0268545.

Pratsinis M, Fankhauser C, Pratsinis K, Beyer J, Bührer E, Cathomas R, Fischer N, Hermanns T, Hirschi-Blickenstorfer A, Kamradt J, Alex Kluth L, Zihler D, Mingrone W, Müller B, Nestler T, Rothschild S, Seifert B, Templeton A, Terbuch A, Ufen M, Woelky R, Gillessen S, Rothermundt C. Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses. *Eur Urol Open Sci* 2022; 40:16–18.

Fankhauser C, Christiansen A, Rothermundt C, Cathomas R, Wettstein M, Grossmann N, Grogg J, Templeton A, Hirschi-Blickenstorfer A, Lorch A, Gillessen S, Moch H, Beyer J, Hermanns T. Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours. *Br J Cancer* 2021; 126:1140–1144.

Omlin A, Zwahlen D, Wyler S, Wild D, Templeton A, Stenner F, Schmid H, Roggero E, Rentsch C, Nitzsche E, Kueng M, Jochum W, Gillessen Sommer S, Eberli D, Beyer J, Spahn M, Cathomas R. [Treatment of Advanced Prostate Carcinoma – an Interdisciplinary Recommendation]. *Praxis (Bern 1994)* 2018; 107:1043–1051.

Baumann M, Templeton A, Ruhstaller T, Riesen W, Mark M, Klingbiel D, Hochstrasser A, Dietrich D, Dani S, Thürlimann B. Vitamin D levels in Swiss breast cancer survivors. *Swiss Med Wkly* 2018; 148:w14576.

Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton A, Früh M. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. *Lung Cancer* 2017; 111:176-181.

Adam R, Diez-Gonzalez L, Ocana A, Seruga B, Amir E, Templeton A. Prognostic role of telomere length in malignancies: A meta-analysis and meta-regression. *Exp Mol Pathol* 2017; 102:455-474.

Templeton A, Thürlimann B, Baumann M, Mark M, Stoll S, Schwizer M, Dietrich D, Ruhstaller T. Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors. *BMC cancer* 2013; 13:153.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch